Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $1.1 million
Deal Type : Private Placement
BetterLife Announces Fully Subscribed Private Placement Financing
Details : The Company will use the proceeds for the advancement of its lead compound BETR-001, a non-hallucinogenic derivative of LSD to treat neuro-psychiatric and neurological disorders.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 29, 2024
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $1.1 million
Deal Type : Private Placement
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
Details : BETR-001, a non-hallucinogenic derivative of LSD in development for major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 14, 2024
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $0.5 million
Deal Type : Private Placement
BetterLife Announces Intent to Complete Private Placement of Units
Details : The Company will advance BETR-001, a non-hallucinogenic LSD derivative, for treating major depressive disorder, anxiety, neuropathic pain, and other neuro-psychiatric disorders.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 03, 2024
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $0.5 million
Deal Type : Private Placement
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $1.1 million
Deal Type : Private Placement
BetterLife Closes $1.168 Million Debentures for LSD-based Drug Studies
Details : The net proceeds will fund the clinical advancement of BETR-001 (2-Bromo-Lysergic Acid Diethylamide), being evaluated for treating major depressive disorder and anxiety disorder.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 03, 2024
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $1.1 million
Deal Type : Private Placement
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
BetterLife Announces Closing of Convertible Debentures for Further Development of BETR-001
Details : Proceeds will advance BETR-001, a non-hallucinogenic 2-bromo-LSD, in development for major depressive disorder, anxiety, and neuropathic pain.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
Details : BETR-001 (2-bromo-LSD) is a non-hallucinogenic and noncontrolled LSD derivative in development for treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2023
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BETR-001 (2-bromo-LSD) is a non-hallucinogenic and noncontrolled LSD derivative in development for treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2023
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ceruvia Lifesciences Announces First Participant Dosed in BOL-148 Phase 1 Clinical Trial
Details : NYPRG-101, also referred to in the literature as BOL-148 (2-bromo-d-lysergic acid diethylamide), is a non-hallucinogenic analog of LSD, differing by only one atom. It is currently in phase 1 clinical trial for migraine and cluster headache.
Brand Name : BOL-148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2023
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Negev Capital
Deal Size : $0.4 million
Deal Type : Private Placement
BetterLife Announces Closing of Private Placement
Details : BETR-001 (2-bromolysergic acid diethylamide), which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self administered.
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 07, 2022
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Negev Capital
Deal Size : $0.4 million
Deal Type : Private Placement
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
Details : BETR-001 (2-bromolysergic acid diethylamide) is a second-generation LSD derivative molecule that does not cause hallucinations. The synthesis of BETR-001 is via non-controlled substance synthetic route, and therefore not subject to controlled substance r...
Brand Name : BETR-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2022
Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?